Drug Trial Radar · NCT03156114
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
Last checked: Nov 19, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
172
Actual
Start
Jun 13, 2017
Primary completion
Mar 9, 2023
Study completion Jun 6, 2023
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- May 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study in adults with advanced solid tumors including non-small cell lung cancer. The study tests the combination of two medicines called BI 754111 and BI 754091 that may help the immune system to fight the cancer. Such medicines are called immune checkpoint inhibitors. The study has two parts. In the first part, doctors want to find out the highest dose of 2 medicines that people with solid tumors can tolerate. This dose is then used for the second part of the study. In the second part, the combination of the two medicines is tested in patients with non-small cell lung cancer and other types of solid cancer. These patients had gotten treatment with anti-PD-1 or anti-PD-L1 medicines but their tumors have come back. The doctors check whether the combination of BI 754111 and BI 754091 makes tumors shrink. Both medicines are given as an infusion into the vein every 3 weeks. If there is benefit for the patients and if they can tolerate it, the treatment is given for maximum of 1 year. During the entire study doctors will regularly check the health of the patients.
Conditions
- Neoplasms
- Carcinoma, Non-Small-Cell Lung
Interventions
EzabenlimabDrug
240 mg ezabenlimab given as an intravenous infusion on day 1 of 21-day cycles (q3w)
BI 754111Drug
Different dosages of BI 754111 given as an intravenous infusion on day 1 of 21-day cycles (q3w).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation: Maximum-tolerated Dose (MTD) of the BI 754111 Plus Ezabenlimab CombinationTime frame: First treatment cycle, the first 21 days following the start of trial medication.
- Dose Escalation: Number of Patients Experiencing DLTs During the Combination MTD Evaluation PeriodTime frame: First treatment cycle, the first 21 days following the start of trial medication.
- Dose Expansion: Number of Patients With Objective Response (OR) - Confirmed Complete Response (CR) and Partial Response (PR)Time frame: From the date of the first administration of trial treatment until the date of the last administration of trial treatment + 30 days (residual effect period), up to 818 days.
Locations
15 sites in 5 countries. Site status is shown where the registry gives one.
University of Miami
Miami, Florida
Florida Cancer Specialists
Sarasota, Florida
John Theurer Cancer Center
Hackensack, New Jersey
Stephenson Cancer Center
Oklahoma City, Oklahoma
Tennessee Oncology, PLLC
Nashville, Tennessee
Froedtert and The Medical College of Wisconsin
Milwaukee, Wisconsin
Cross Cancer Institute (University of Alberta)
Edmonton, Alberta, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
BioVirtus Research Site Sp. z o.o.
Józefów, Poland
Oncology Center-Maria Sklodowska-Curie Institute
Warsaw, Poland
Hospital Universitari Dexeus
Barcelona, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Hospital Universitario HM Sanchinarro
Madrid, Spain
Hospital Politècnic La Fe
Valencia, Spain
Sarah Cannon Research Institute
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.